<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02300142</url>
  </required_header>
  <id_info>
    <org_study_id>GEN-003-002a</org_study_id>
    <nct_id>NCT02300142</nct_id>
  </id_info>
  <brief_title>Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study</brief_title>
  <official_title>Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 - Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Combinations of GEN-003 and Matrix-M2 in Subjects With Genital HSV-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genocea Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genocea Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a voluntary study to allow subjects who received placebo while on GEN-003-002 to be
      randomized, in a blinded manner, to 1 of 6 active combinations of GEN-003 and Matrix-M2.

      Objectives:

        -  To compare the impact on clinical Herpes Simplex Virus type-2 (HSV-2) disease among 6
           different combinations of GEN-003 antigens and Matrix-M2 adjuvant measured by:

             -  Time to first clinical and/or virologic recurrence after Dose 3 (Day 43)

             -  Proportion of subjects who are recurrence free at 6 and 12 months after the last
                dose of vaccine

             -  Lesion rate (percent of days with genital lesions present) during the
                post-vaccination follow-up period

             -  Antiviral use.

        -  To evaluate the safety and tolerability of GEN-003 in combination with Matrix-M2.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Impact on clinical HSV-2 disease based on time to recurrence and lesion rate</measure>
    <time_frame>53 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events as a measure of safety and tolerability</measure>
    <time_frame>57 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Genital Herpes Simplex Type 2</condition>
  <arm_group>
    <arm_group_label>GEN-003 Vaccine 30μg / Matrix-M 25μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GEN-003 Vaccine 30μg / Matrix-M2 50μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GEN-003 Vaccine 30μg / Matrix-M2 75μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GEN-003 Vaccine 60μg / Matrix-M2 25μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GEN-003 Vaccine 60μg / Matrix-M2 50μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GEN-003 Vaccine 60μg / Matrix-M2 75μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GEN-003 Vaccine (30μg of each antigen)</intervention_name>
    <description>HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D</description>
    <arm_group_label>GEN-003 Vaccine 30μg / Matrix-M 25μg</arm_group_label>
    <arm_group_label>GEN-003 Vaccine 30μg / Matrix-M2 50μg</arm_group_label>
    <arm_group_label>GEN-003 Vaccine 30μg / Matrix-M2 75μg</arm_group_label>
    <other_name>HSV Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GEN-003 Vaccine (60μg of each antigen)</intervention_name>
    <description>HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D</description>
    <arm_group_label>GEN-003 Vaccine 60μg / Matrix-M2 25μg</arm_group_label>
    <arm_group_label>GEN-003 Vaccine 60μg / Matrix-M2 50μg</arm_group_label>
    <arm_group_label>GEN-003 Vaccine 60μg / Matrix-M2 75μg</arm_group_label>
    <other_name>HSV Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Matrix-M2 Adjuvant (25μg)</intervention_name>
    <description>Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.</description>
    <arm_group_label>GEN-003 Vaccine 30μg / Matrix-M 25μg</arm_group_label>
    <arm_group_label>GEN-003 Vaccine 60μg / Matrix-M2 25μg</arm_group_label>
    <other_name>MM2</other_name>
    <other_name>Adjuvant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Matrix-M2 Adjuvant (50μg)</intervention_name>
    <description>Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.</description>
    <arm_group_label>GEN-003 Vaccine 30μg / Matrix-M2 50μg</arm_group_label>
    <arm_group_label>GEN-003 Vaccine 60μg / Matrix-M2 50μg</arm_group_label>
    <other_name>MM2</other_name>
    <other_name>Adjuvant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Matrix-M2 Adjuvant (75μg)</intervention_name>
    <description>Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.</description>
    <arm_group_label>GEN-003 Vaccine 30μg / Matrix-M2 75μg</arm_group_label>
    <arm_group_label>GEN-003 Vaccine 60μg / Matrix-M2 75μg</arm_group_label>
    <other_name>MM2</other_name>
    <other_name>Adjuvant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who received placebo in GEN-003-002 and completed the study through Day 71
             per protocol, including the collection of at least 45 anogenital swabs during Days 43
             to 71.

          2. Enrolled into this trial within 56 days of completing Day 71 of GEN-003-002.

          3. Willing and able to provide written informed consent.

          4. Willing to perform and comply with all study procedures including attending clinic
             visits as scheduled.

          5. Men and women of childbearing potential, must be willing to practice a highly
             effective method of contraception that may include, but is not limited to, abstinence,
             monogamous relationship with vasectomized partner, vasectomy, licensed hormonal
             methods, intrauterine device (IUD), or barrier method (e.g., condom, diaphragm) for 28
             days before and 90 days after receiving Study Drug.

        Exclusion Criteria:

          1. On suppressive antiviral medication within 7 days prior to the first dose of Study
             Drug.

          2. Collection of less than 45 anogenital swabs during Days 43 to 71 of the GEN-003-002
             study.

          3. History of any form of ocular Herpes Simplex Virus (HSV) infection, HSV-related
             erythema multiforme, or herpes meningitis or encephalitis.

          4. Immunocompromised individuals, including those receiving immunosuppressive doses of
             corticosteroids (more than 20 mg of prednisone given daily or on alternative days for
             2 weeks or more within 6 months prior to the first dose of Study Drug, any dose of
             corticosteroids within 30 days of the first dose of Study Drug, or high dose inhaled
             corticosteroids [&gt; 960 μg/day of beclomethasone dipropionate or equivalent]) or other
             immunosuppressive agents.

          5. Presence or history of autoimmune disease, regardless of current treatment.

          6. Positive serologic test for Human Immunodeficiency Virus (HIV-1) or hepatitis C
             infection (in the absence of a negative PCR result); positive hepatitis B surface
             antigen (HBsAg) within 6 months prior to the first dose of Study Drug.

          7. Clinically significant laboratory abnormality or a value ≥ Grade 2 within 56 days
             prior to the first dose of Study Drug.

          8. Receipt of blood products within 90 days prior to the first dose of Study Drug.

          9. Receipt of a live vaccine within 28 days prior to or a subunit vaccine within 14 days
             prior to the first dose of Study Drug or planned vaccination within 30 days following
             the last dose of Study Drug.

         10. Pregnant or nursing women.

         11. History of drug or alcohol abuse that, in the opinion of the Investigator, would
             interfere with the patient's ability to comply with the requirements of the study.

         12. Other active, uncontrolled co-morbidities that, in the opinion of the Investigator,
             would make the subject unsuitable for the study or unable to comply with the study
             requirements.

        NOTE: Subjects who are taking a medication to control an underlying co-morbidity may be
        enrolled if there have been no changes to their medication within 60 days prior to the
        first dose of Study Drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama Vaccine Research Unit</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quest Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois Department of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Infectious Disease Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Fenway Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Global HIV Prevention and Treatment Clinical Trials Unit</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westover Heights Clinic</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magee-Womens Hospital of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tekton Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>98745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies - Clear Lake/Webster</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UW Virology Research Clinic</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2014</study_first_submitted>
  <study_first_submitted_qc>November 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2014</study_first_posted>
  <disposition_first_submitted>September 11, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>September 11, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 18, 2017</disposition_first_posted>
  <last_update_submitted>October 6, 2017</last_update_submitted>
  <last_update_submitted_qc>October 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HSV</keyword>
  <keyword>Herpes</keyword>
  <keyword>genital infection</keyword>
  <keyword>vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Simplex</mesh_term>
    <mesh_term>Herpes Genitalis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

